NCT04239014 - A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. | Biotech Hunter

Timeline

Start Date

August 7, 2020

Primary Completion Date

January 25, 2021

Study Completion Date

January 25, 2021

Conditions

Ovarian Cancer

Interventions

DRUG

Olaparib

Olaparib 300 mg BD (2 × 150 mg tablets) continually in the olaparib monotherapy and ceralasertib+olaparib treatment arms.

DRUG

Ceralasertib

Ceralasertib 160 mg QD (2 × 80 mg tablets) from Days 1 to 7 (inclusive) of every 28-day cycle.

DRUG

Placebo to match olaparib

Per olaparib

Trial Locations (26)

8035

Research Site, Barcelona

19001

Research Site, Abington

19104

Research Site, Philadelphia

30342

Research Site, Atlanta

33612

Research Site, Tampa

40202

Research Site, Louisville

44106

Research Site, Cleveland

57105

Research Site, Sioux Falls

70433

Research Site, Covington

73104

Research Site, Oklahoma City

74146

Research Site, Tulsa

77030

Research Site, Houston

80131

Research Site, Napoli

90048

Research Site, Los Angeles

90806

Research Site, Long Beach

97210

Research Site, West Hollywood

Research Site, Portland

98104

Research Site, Seattle

99508

Research Site, Anchorage

92093-0021

Research Site, La Jolla

06106

Research Site, Hartford

07932

Research Site, Florham Park

07666

Research Site, Teaneck

57105-1599

Research Site, Sioux Falls

M5G 2M9

Research Site, Toronto

H3A 1A1

Research Site, Montreal